Pharmaceutical Composition Containing 2-{4-[N-(5,6-Diphenylpyrazin-2-Yl)-N-Isopropylamino]Butyloxy}-N-(Methylsulfonyl)Acetamide
Patent No. EP4331607 (titled "Pharmaceutical Composition Containing 2-{4-[N-(5,6-Diphenylpyrazin-2-Yl)-N-Isopropylamino]Butyloxy}-N-(Methylsulfonyl)Acetamide") was filed by Nippon Shinyaku on Dec 1, 2016. The application was issued on Apr 30, 2025.
Patent Summary
A stabilized solid preparation comprises 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide (Compound (I)) and D-mannitol. To suppress the decomposition of Compound (I) and improve storage stability, the D-mannitol must have a specific surface area of 1.0 m²/g or less. The D-mannitol content ranges from 10 to 99 wt% of the total weight of the solid preparation and accounts for 20 wt% or more of the total weight of all diluents contained therein. Compound (I) acts as a prostaglandin I2 receptor agonist, providing platelet aggregation inhibitory, vasodilating, bronchial smooth muscle dilating, lipid deposition inhibitory, and leukocyte activation inhibitory effects.
Patent Family
Patent Oppositions (2)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
EP4331607
- Application Number
- EP23214939A
- Filing Date
- Dec 1, 2016
- Status
- Granted And Under Opposition
- Mar 28, 2025
- Publication Date
- Apr 30, 2025
- External Links
- Slate, Register , Google Patents